Carl Sadowsky

15.6k total citations · 1 hit paper
67 papers, 3.2k citations indexed

About

Carl Sadowsky is a scholar working on Psychiatry and Mental health, Physiology and Pharmacology. According to data from OpenAlex, Carl Sadowsky has authored 67 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Psychiatry and Mental health, 28 papers in Physiology and 15 papers in Pharmacology. Recurrent topics in Carl Sadowsky's work include Dementia and Cognitive Impairment Research (28 papers), Alzheimer's disease research and treatments (26 papers) and Cholinesterase and Neurodegenerative Diseases (15 papers). Carl Sadowsky is often cited by papers focused on Dementia and Cognitive Impairment Research (28 papers), Alzheimer's disease research and treatments (26 papers) and Cholinesterase and Neurodegenerative Diseases (15 papers). Carl Sadowsky collaborates with scholars based in United States, Switzerland and France. Carl Sadowsky's co-authors include James E. Galvin, Mark A. Mintun, Daniel Skovronsky, Alan Carpenter, Abhinay D. Joshi, Michael J. Pontecorvo, P. Murali Doraiswamy, Marwan N. Sabbagh, George T. Grossberg and Adam Fleisher and has published in prestigious journals such as JAMA, Neurology and The Lancet Neurology.

In The Last Decade

Carl Sadowsky

66 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

2012 572 citations Christopher M. Clark, Michael J. Pontecorvo et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carl Sadowsky United States	29	1.7k	1.6k	614	610	465	67	3.2k
J. Wesson Ashford United States	39	2.0k 1.2×	2.0k 1.2×	485 0.8×	868 1.4×	515 1.1×	147	5.2k
Eric McDade United States	31	2.0k 1.2×	1.8k 1.1×	328 0.5×	978 1.6×	517 1.1×	97	4.5k
Lutz Froelich Germany	19	1.4k 0.8×	1.9k 1.1×	569 0.9×	369 0.6×	658 1.4×	54	3.9k
Richard Harvey United Kingdom	25	1.2k 0.7×	1.2k 0.7×	488 0.8×	461 0.8×	510 1.1×	56	3.3k
Alireza Atri United States	35	2.0k 1.2×	1.7k 1.0×	727 1.2×	1.2k 2.0×	519 1.1×	119	5.0k
Jessica B. Langbaum United States	31	2.1k 1.3×	2.0k 1.2×	291 0.5×	886 1.5×	475 1.0×	109	3.8k
Linda M. Ercoli United States	35	2.0k 1.2×	2.1k 1.3×	503 0.8×	1.1k 1.9×	541 1.2×	97	5.1k
Andrew Satlin United States	45	2.1k 1.3×	1.9k 1.1×	985 1.6×	1.4k 2.3×	495 1.1×	103	6.9k
Samantha C. Burnham Australia	30	2.2k 1.3×	2.7k 1.7×	301 0.5×	779 1.3×	677 1.5×	101	4.6k
Douglas Galasko United States	27	1.5k 0.9×	1.7k 1.1×	332 0.5×	456 0.7×	464 1.0×	45	3.3k

Countries citing papers authored by Carl Sadowsky

Since Specialization

Citations

This map shows the geographic impact of Carl Sadowsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl Sadowsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl Sadowsky more than expected).

Fields of papers citing papers by Carl Sadowsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carl Sadowsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl Sadowsky. The network helps show where Carl Sadowsky may publish in the future.

Co-authorship network of co-authors of Carl Sadowsky

This figure shows the co-authorship network connecting the top 25 collaborators of Carl Sadowsky. A scholar is included among the top collaborators of Carl Sadowsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carl Sadowsky. Carl Sadowsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abushakra, Susan, Anton P. Porsteinsson, Philip Scheltens, et al.. (2017). CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL. The Journal of Prevention of Alzheimer s Disease. 4(3). 1–8. 61 indexed citations

Pontecorvo, Michael J., Andrew Siderowf, Bruno Dubois, et al.. (2017). Effectiveness of Florbetapir PET Imaging in Changing Patient Management. Dementia and Geriatric Cognitive Disorders. 44(3-4). 129–143. 32 indexed citations

Farlow, Martin R., et al.. (2015). Evaluating Response to High‐Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease. CNS Neuroscience & Therapeutics. 21(6). 513–519. 13 indexed citations

Farlow, Martin, et al.. (2014). Predictors of Response to 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer’s Disease (P1.007). Neurology. 82(10_supplement). 2 indexed citations

Farlow, Martin R., George T. Grossberg, Carl Sadowsky, Xiangyi Meng, & Drew M. Velting. (2014). A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease. Alzheimer Disease & Associated Disorders. 29(2). 110–116. 12 indexed citations

Sadowsky, Carl, et al.. (2014). Rivastigmine From Capsules to Patch. The Primary Care Companion For CNS Disorders. 16(5). 24 indexed citations

Johnson, Keith A., Reisa A. Sperling, Christopher Gidicsin, et al.. (2013). Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimer s & Dementia. 9(5S). S72–83. 190 indexed citations

Shah, Raj C., Patrick Kamphuis, Sue E. Leurgans, et al.. (2013). The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease. Alzheimer s Research & Therapy. 5(6). 59–59. 77 indexed citations

Grundman, Michael, Michael J. Pontecorvo, Stephen Salloway, et al.. (2012). Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline. Alzheimer Disease & Associated Disorders. 27(1). 4–15. 93 indexed citations

10.

Joshi, Abhinay D., Michael J. Pontecorvo, Alan Carpenter, et al.. (2012). Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects. Journal of Nuclear Medicine. 53(3). 378–384. 301 indexed citations

11.

Fleisher, Adam, Kewei Chen, Xiaofen Liu, et al.. (2012). Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiology of Aging. 34(1). 1–12. 159 indexed citations

12.

Sperling, Reisa A., Keith A. Johnson, P. Murali Doraiswamy, et al.. (2012). Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiology of Aging. 34(3). 822–831. 105 indexed citations

13.

Sadowsky, Carl & James E. Galvin. (2012). Guidelines for the Management of Cognitive and Behavioral Problems in Dementia. The Journal of the American Board of Family Medicine. 25(3). 350–366. 92 indexed citations

14.

Winner, Paul, et al.. (2012). Concurrent OnabotulinumtoxinA Treatment of Cervical Dystonia and Concomitant Migraine. Headache The Journal of Head and Face Pain. 52(8). 1219–1225. 20 indexed citations

15.

Sadowsky, Carl, George T. Grossberg, Monique Somogyi, & Xiangyi Meng. (2011). Predictors of Sustained Response to Rivastigmine in Patients With Alzheimer’s Disease. The Primary Care Companion For CNS Disorders. 13(3). 3 indexed citations

16.

Grossberg, George T., Carl Sadowsky, Hans Förstl, et al.. (2009). Safety and Tolerability of the Rivastigmine Patch. Alzheimer Disease & Associated Disorders. 23(2). 158–164. 36 indexed citations

17.

Winblad, Bengt, Jeffrey L. Cummings, Niels Andreasen, et al.. (2007). A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry. 22(5). 456–467. 225 indexed citations

18.

Sadowsky, Carl, et al.. (2005). Switching From Donepezil to Rivastigmine Is Well Tolerated. The Primary Care Companion For CNS Disorders. 7(2). 43–48. 20 indexed citations

19.

Wolkowitz, Owen M., Joel H. Kramer, Victor I. Reus, et al.. (2003). DHEA treatment of Alzheimer’s disease. Neurology. 60(7). 1071–1076. 72 indexed citations

20.

Freitag, Frederick G., Roger Cady, Arthur H. Elkind, et al.. (2001). Comparative Study of a Combination of Isometheptene Mucate, Dichloralphenazone With Acetaminophen and Sumatriptan Succinate in the Treatment of Migraine. Headache The Journal of Head and Face Pain. 41(4). 391–398. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact